RE:RE:RE:Happy to average down at these prices!! You bring up several points/opinions worth discussing further:
the project 21 is $200 per month or $2400 per patient per annum. I would imagine most customers will maximize this benefit. Who turns away free money? Naprawa has acknowledged on the last quarterly presentation they're expecting overall margins in the 50% range across all markets and Tejinder acknowledged on one of his webinars that because they're running asset lite in Europe, margins will be pinched so for now the jury is out on exactly how margins shake out on this project . If khiron gets 20% of the patient base in this project, the revenues alone are close to $10M. Admittedly, the patient registry at current pace will not be filled until next Spring or Summer. There's another excellent webinar with Tejinder and David Nutt on this project (lots of informative stuff on their site) Also there's the cancard development, which helps to completely decrminalize medical cannabis possession . The UK is just beginning and to dismiss khirons involvement as merely a PR opportunity is to implicitly acknowledge just how uninformed you are about the UK opportunity.
As for Mexico legalization, Alvarro recently stated he believes it's a go by February 21. Khiron is obviously already positioning themselves there. It will be a very competitive market no doubt . I'll take Alvarro's far better informed opinion on Mexico than anyone on a message board. And yes we're all aware the can has been kicked down the road again and again as the government continues to turn a blind eye to the Supreme Court directive.
The elephant in the room is Brazil imo. Again, khiron is going in asset lite but with a very expansive distribution network. Brazil will be far more competitive than Columbia but any positive or significant developments reported in that market would certainly have potential to move the stock price. Another outlier for now is Germany although recently Alvarro said they're expecting to get at least mid single digit share of the flower market, which would be a surprisingly good start if that transpires.
in regards to the CFO, I have nothing against the guy but I was extremely disappointed by the appointment. This company is gearing up in many markets and looking to prove the growth trajectory of its medical model. They need a seasoned CFO with 20 plus years preferably a man or woman who oversaw and participated in a small to mid cap company growth path. My hope is once the company has closed the cash burn they hastily remedy this mistake. But I disagree with your premise as to why the former CFO left, that's just baseless conjecture.
Technically, the chart is fugly. The support at .40 gave way so let's see how it handles the previous low at .30. Im watching very closely for key reversal potential. I'd imagine we will see management buying if the stock continues plumbing the .30s as long as it's not a closed period. But they will not employ the share buyback again as they need that capital. All imo